KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Palvella Therapeutics (PVLA) Shares Outstanding (Weighted Average): 2014-2024

Historic Shares Outstanding (Weighted Average) for Palvella Therapeutics (PVLA) over the last 10 years, with Dec 2024 value amounting to $1.3 million.

  • Palvella Therapeutics' Shares Outstanding (Weighted Average) rose 6.85% to $1.3 million in Q4 2024 from the same period last year, while for Sep 2024 it was $1.3 million, marking a year-over-year increase of 6.85%. This contributed to the annual value of $1.3 million for FY2024, which is 6.85% up from last year.
  • As of Q4 2024, Palvella Therapeutics' Shares Outstanding (Weighted Average) stood at $1.3 million, which was down 0.00% from $1.3 million recorded in Q3 2024.
  • Palvella Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $1.3 million for Q2 2024, and its period low was $654,008 during Q2 2020.
  • In the last 3 years, Palvella Therapeutics' Shares Outstanding (Weighted Average) had a median value of $1.1 million in 2023 and averaged $1.1 million.
  • Data for Palvella Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY soared of 32.85% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Palvella Therapeutics' Shares Outstanding (Weighted Average) stood at $699,632 in 2020, then rose by 28.75% to $900,777 in 2021, then climbed by 3.25% to $930,078 in 2022, then soared by 32.85% to $1.2 million in 2023, then rose by 6.85% to $1.3 million in 2024.
  • Its Shares Outstanding (Weighted Average) stands at $1.3 million for Q4 2024, versus $1.3 million for Q3 2024 and $1.3 million for Q2 2024.